Q2 Earnings Estimate for CLPT Issued By Lake Street Capital

ClearPoint Neuro, Inc. (NASDAQ:CLPT) – Investment analysts at Lake Street Capital issued their Q2 2026 earnings per share estimates for ClearPoint Neuro in a research report issued to clients and investors on Monday, July 27th. Lake Street Capital analyst F. Takkinen forecasts that the company will earn ($0.33) per share for the quarter. The consensus estimate for ClearPoint Neuro’s current full-year earnings is ($1.05) per share.

ClearPoint Neuro (NASDAQ:CLPT) last announced its earnings results on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). The company had revenue of $12.13 million during the quarter, compared to analysts’ expectations of $11.97 million. ClearPoint Neuro had a negative return on equity of 140.96% and a negative net margin of 71.57%.

Several other research firms have also commented on CLPT. B. Riley Financial lifted their price objective on shares of ClearPoint Neuro from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a research note on Friday, July 17th. Finally, Stifel Nicolaus set a $16.00 target price on shares of ClearPoint Neuro in a report on Tuesday, June 9th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $23.00.

ClearPoint Neuro Stock Performance

NASDAQ:CLPT opened at $14.53 on Wednesday. The stock’s fifty day moving average is $15.20 and its 200 day moving average is $13.07. ClearPoint Neuro has a fifty-two week low of $8.27 and a fifty-two week high of $30.10. The firm has a market capitalization of $435.75 million, a PE ratio of -14.39 and a beta of 1.23. The company has a debt-to-equity ratio of 2.63, a quick ratio of 4.88 and a current ratio of 5.79.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Commonwealth Equity Services LLC increased its stake in ClearPoint Neuro by 1.7% in the 4th quarter. Commonwealth Equity Services LLC now owns 65,557 shares of the company’s stock worth $897,000 after buying an additional 1,109 shares during the period. Price T Rowe Associates Inc. MD boosted its position in ClearPoint Neuro by 4.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 26,791 shares of the company’s stock valued at $367,000 after buying an additional 1,204 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in ClearPoint Neuro in the 4th quarter valued at about $25,000. BNP Paribas Financial Markets grew its stake in ClearPoint Neuro by 2,435.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock worth $27,000 after acquiring an additional 2,143 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its position in shares of ClearPoint Neuro by 1,079.0% during the third quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock worth $51,000 after acquiring an additional 2,158 shares during the period. 30.08% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Timothy T. Richards sold 5,415 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $12.17, for a total transaction of $65,900.55. Following the completion of the sale, the director directly owned 87,198 shares of the company’s stock, valued at approximately $1,061,199.66. This trade represents a 5.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Matthew B. Klein sold 16,000 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $11.59, for a total value of $185,440.00. Following the transaction, the director owned 46,935 shares of the company’s stock, valued at approximately $543,976.65. The trade was a 25.42% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 108,349 shares of company stock valued at $1,796,118. Corporate insiders own 6.94% of the company’s stock.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.